HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Raises Price Target to $120
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained a Buy rating on Praxis Precision Medicine (NASDAQ:PRAX) and raised the price target from $105 to $120.
August 15, 2024 | 10:26 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained a Buy rating on Praxis Precision Medicine and raised the price target from $105 to $120.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100